Home › Trial NCT00522145
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
- Trial IDNCT00522145
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorKadmon Corporation, LLC
- Enrollment41
- Start date2007-05
- ConditionsCarcinoma, Non-Small-Cell Lung
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.